688192 Dizal Pharmaceutical
- 44.00
- +2.40+5.77%
Dizal Pharmaceutical News
Dizhe Pharmaceutical: Dizhe Pharmaceutical: Voluntary Disclosure Notice on Schwarzhe\'s First-Line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR 20 Exon Insertion Mutation Obtaining CDE Breakthrough Treatment
Dizhe Pharmaceutical: Voluntary Disclosure Notice on Schwarzhe\'s First-Line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR 20 Exon Insertion Mutation Obtaining CDE Breakthrough Treatment
Di Zhe Pharmaceutical: Legal Opinion of Beijing Zhonglun Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Di Zhe (Jiangsu) Pharmaceutical Co., Ltd.
Dizhe Pharmaceutical: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Digel Pharmaceutical Investor Relations Activity Record Table_2024 Semi-Annual Science and Technology Innovation Board Pharmaceutical and Biological Products Group Performance Briefing
Digel Pharmaceuticals Investor Relations Activity Record List_August-September 2024
Digel Pharmaceuticals: Dizhe Pharmaceutical: Voluntary Disclosure of the Report on Schwarzhe\'s Globally Registered Clinical Research Subgroup Data Selected for the 2024 European Society of Medical Oncology (ESMO) Conference
Dizhe Pharmaceutical: Announcement on voluntary disclosure of the report of Schwarzer\'s globally registered clinical research subgroup data selected for the 2024 European Society of Medical Oncology (ESMO) Conference
Dizhe Pharmaceutical: 2024 Second Extraordinary General Meeting of Shareholders Meeting Information
Dizhe Pharmaceutical: Huatai United Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Digi (Jiangsu) Pharmaceutical Co., Ltd.
Dizhe Pharmaceutical: Announcement on participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Dizhe Pharmaceutical: Announcement of Resolutions of the Seventh Meeting of the 2nd Board of Supervisors
Dizhe Pharmaceutical: Special Report on the Storage and Actual Use of Funds Raised for the 2024 Semi-Annual Year
Dizhe Pharmaceutical: Semi-annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Value Return” Action Plan
Dizhe Pharmaceutical: Announcement of Resolutions of the Eighth Meeting of the 2nd Board of Directors
Digel Pharmaceuticals: 2024 Semi-Annual Report
Digel Pharmaceuticals: 2024 Semi-Annual Report Summary
Dizhe Pharmaceutical: Report on the use of previously raised funds
Dizhe Pharmaceutical: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Dizhe Pharmaceutical: Announcement on the change of accounting firm
Analysis
Price Target
No Data
No Data